Targeting histone deacetylases for the treatment of immune, endocrine and metabolic disorders
Lawless, M. W., Norris, S., O'Byrne, Kenneth J., & Gray, Stephen G. (2009) Targeting histone deacetylases for the treatment of immune, endocrine and metabolic disorders. Endocrine, Metabolic and Immune Disorders - Drug Targets, 9(1), pp. 84-107.
The 'histone code' is a well-established hypothesis describing the idea that specific patterns of post-translational modifications to histones act like a molecular "code" recognised and used by non-histone proteins to regulate specific chromatin functions. One modification which has received significant attention is that of histone acetylation. The enzymes which regulate this modification are described as histone acetyltransferases or HATs, and histone deacetylases or HDACs. Due to their conserved catalytic domain HDACs have been actively targeted as a therapeutic target. The proinflammatory environment is increasingly being recognised as a critical element for both degenerative diseases and cancer. The present review will discuss the current knowledge surrounding the clinical potential & current development of histone deacetylases for the treatment of diseases for which a proinflammatory environment plays important roles, and the molecular mechanisms by which such inhibitors may play important functions in modulating the proinflammatory environment. © 2009 Bentham Science Publishers Ltd.
Impact and interest:
Citation counts are sourced monthly from and citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
|Item Type:||Journal Article|
|Keywords:||Breast, Chaperone, Diabetes, Histone deacetylase, Lupus, Multiple sclerosis, Pancreas, 4 [n (2 hydroxyethyl) n [2 (3 indolyl)ethyl]aminomethyl]cinnamohydroxamic acid, 4 n acetyldinaline, 4 phenylbutyric acid, 5 aza 2' deoxycytidine, alpha interferon, antineoplastic agent, B lymphocyte induced maturation protein 1, Daxx protein, DNA methyltransferase inhibitor, epirubicin, flavopiridol, fluorouracil, gemcitabine, histone acetyltransferase, histone deacetylase inhibitor, immunoglobulin enhancer binding protein, n (2 aminophenyl) 4 (3 pyridinylmethoxycarbonylaminomethyl)benzamide, paclitaxel, romidepsin, sk 7041, tamoxifen, transcription factor FOXP3, trastuzumab, trichostatin A, tumor necrosis factor related apoptosis inducing ligand, unclassified drug, unindexed drug, valproic acid, vatalanib, vorinostat, acute granulocytic leukemia, advanced cancer, bladder cancer, breast cancer, cell protection, clinical trial, colorectal cancer, cutaneous T cell lymphoma, cystic fibrosis, diabetes mellitus, disease model, drug mechanism, drug potentiation, drug targeting, embryonic stem cell, endocrine disease, endoplasmic reticulum stress, enzyme activity, glioma, head and neck cancer, hematologic malignancy, human, Huntington chorea, immune system, immunopathology, inflammation, kidney carcinoma, large cell lymphoma, leukemia, lung cancer, lung non small cell cancer, melanoma, mesothelioma, metabolic disorder, multiple myeloma, myelodysplastic syndrome, neuroendocrine tumor, nonhuman, obesity, ovary carcinoma, pancreas adenocarcinoma, pancreas cancer, pancreas islet beta cell, recurrent cancer, review, solid tumor, spinal muscular atrophy, systemic lupus erythematosus, T cell lymphoma|
|Divisions:||Current > Schools > School of Biomedical Sciences
Current > QUT Faculties and Divisions > Faculty of Health
Current > Institutes > Institute of Health and Biomedical Innovation
|Copyright Owner:||Copyright 2009 Bentham Science Publishers Ltd.|
|Deposited On:||06 Dec 2013 03:14|
|Last Modified:||12 Mar 2014 05:30|
Repository Staff Only: item control page